Greenland Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Greenland Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$809K	Sell	30,000 -27,500	-48%	-$755K	0.1%	165
2026 Q1	$1.56M	Sell	57,500 -11,500	-17%	-$337K	0.2%	96
2025 Q4	$2.5M	Sell	69,000 -36,853	-35%	-$1.48M	0.27%	93
2025 Q3	$4.01M	Buy	105,853 +95,853	+959%	+$2.07M	0.4%	73
2025 Q2	$135K	Sell	10,000 -10,000	-50%	-$145K	0.01%	311
2025 Q1	$318K	Buy	+20,000	New	+$230K	0.04%	241

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Greenland Capital Management's MLYS Position: Q2 2026 in Review

Greenland Capital Management reduced its Mineralys Therapeutics (MLYS) stake by 48% in Q2 2026, selling an estimated $755K and leaving 30,000 shares worth $809K. The position accounts for 0.1% of the portfolio, ranked #165.

Greenland Capital Management first reported a position in MLYS in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.01M in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Greenland Capital Management held 30,000 shares of Mineralys Therapeutics worth $809K as of Q2 2026.
Greenland Capital Management sold 27,500 Mineralys Therapeutics shares in Q2 2026, an estimated $755K.
Mineralys Therapeutics made up 0.1% of Greenland Capital Management's portfolio in Q2 2026, its #165 holding.
Greenland Capital Management first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 6 quarters since.
Greenland Capital Management's Mineralys Therapeutics position peaked at $4.01M in Q3 2025.
224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Greenland Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.